Wolbachia-carrying mosquitoes reduced dengue in a large Indonesian trial. The World Health Organization is still finalising its global recommendation, expected in late 2027.
What Wolbachia is and why it matters
Wolbachia is a bacterium that occurs naturally inside many insects, including some mosquitoes. The World Health Organization describes it as a naturally occurring intracellular bacterium that can be introduced into Aedes mosquito populations. The aim is to reduce the ability of those mosquitoes to transmit viral infections such as dengue virus. The approach is called population replacement. Researchers breed and release mosquitoes that carry Wolbachia, and these mate with wild mosquitoes. The bacterium then passes to later generations, so the local mosquito population gradually carries it too. Once established, that population transmits dengue, chikungunya and Zika viruses less efficiently. This matters because dengue is a serious illness and because existing control tools, such as insecticide spraying and removing standing water, often struggle to hold mosquito numbers down.
Aedes aegypti: the mosquito behind urban dengue
The mosquito at the centre of this work is Aedes aegypti. It breeds in small containers of water close to homes, bites during daylight, and thrives in dense towns and cities. Those habits make dengue hard to control with standard measures alone. The World Health Organization notes that Wolbachia can reduce the capacity of Aedes aegypti to transmit dengue virus and related viruses. This is why researchers focus on replacing the local population rather than killing every mosquito. A bacterium that spreads on its own through mating offers a lasting change, not a repeated chemical treatment. It also fits a simple prevention message: fewer competent mosquitoes means fewer infected bites, even while household steps such as covering water stores and clearing containers remain important.
The Yogyakarta trial and its design
The strongest evidence comes from a trial in Yogyakarta, Indonesia. Utarini, Indriani, Ahmad and the AWED study group published the results in the New England Journal of Medicine in 2021. The design was a cluster-randomised trial across 24 geographic clusters in Yogyakarta City. Twelve clusters received deployments of wMel-infected Aedes aegypti and twelve served as untreated controls. The researchers screened 8,144 people. They included 6,306 participants aged 3 to 45 years who had acute undifferentiated fever lasting one to four days in the primary analysis. Of these, 2,905 were in the intervention arm and 3,401 were in the control arm. Cluster randomisation compares whole neighbourhoods rather than individuals, which suits an intervention that spreads through a mosquito population.
What the Yogyakarta results showed
Virologically confirmed dengue occurred in 67 of 2,905 people, or 2.3 per cent, in the wMel-treated arm. In the untreated arm it occurred in 318 of 3,401 people, or 9.4 per cent. That gives a protective efficacy of 77.1 per cent, with a 95 per cent confidence interval of 65.3 to 84.9. Hospitalisation occurred in 13 of 2,905 people, or 0.4 per cent, against 102 of 3,401 people, or 3 per cent. That is a protective efficacy of 86.2 per cent, with a confidence interval of 66.2 to 94.3. The monthly median cluster-level wMel prevalence was 95.8 per cent, interquartile range 91.5 to 97.8 per cent, across 27 months of clinical surveillance. The authors conclude that wMel introgression reduced symptomatic dengue and led to fewer dengue hospitalisations.
How WHO first assessed the approach
The World Health Organization reported in September 2020 that the three-year Indonesia trial showed promising results. Its news item stated that dengue cases decreased significantly in areas where Wolbachia-carrying mosquitoes were released compared with untreated areas. That item did not publish the percentage reductions, which belong to the peer-reviewed journal report. It said the results would go to the WHO Vector Control Advisory Group in December for formal assessment of the strategy's impact. In 2020 that advisory group reviewed evidence from field trials on population replacement conducted in multiple countries. It concluded that the intervention had demonstrated epidemiological impact. This was an early milestone: an expert group accepted that the method could affect disease, not merely mosquito biology.
Field releases in several countries
Releases have not been confined to one country. A World Health Organization feature story from 2016 described work in Australia, Indonesia and Vietnam. It also described releases in Jurujuba in Niteroi, Brazil, following an initial project near the Rio de Janeiro international airport in 2014. At that time the article reported no concrete outcome data and framed the method as promising rather than comprehensive. The 2026 WHO update records that several countries and partners are already implementing or evaluating these approaches. The evidence base has expanded, with results from a broad range of study types and a growing number of implementation settings. That wider experience matters because a method that works in one city still has to be prepared, monitored and sustained elsewhere.
Where the global guidance stands now
The World Health Organization update of 11 June 2026 sets out the current position. A new systematic review is under way, incorporating the present evidence. The integrated vector control Guideline Development Group is expected to convene in the first quarter of 2027, and publication of recommendations is anticipated in late 2027. WHO is separately developing an operational manual to guide country preparation and implementation of the intervention as appropriate. Finalisation of that manual depends on the outcomes of the Guideline Development Group. Until then, readers should treat Wolbachia releases as an evidence-backed public health method that is still moving through formal global guidance. No single release protects a household by itself. Physical barriers and mosquito control remain part of the picture, and every figure here comes from the cited trial report.
Sources
- WHO update on the assessment of Wolbachia population replacement for the control of Aedes-borne diseases: World Health Organization
- Can tiny bacteria help stop the spread of disease?: World Health Organization
- Dengue control: three-year Indonesia trial shows promising results: World Health Organization
- Efficacy of Wolbachia-infected mosquito deployments for the control of dengue: New England Journal of Medicine